Pharvaris Management

Management criteria checks 3/4

Pharvaris' CEO is Berndt Axel Modig, appointed in Sep 2015, has a tenure of 9.17 years. total yearly compensation is €532.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 2.77% of the company’s shares, worth $35.65M. The average tenure of the management team and the board of directors is 2.8 years and 3.8 years respectively.

Key information

Berndt Axel Modig

Chief executive officer

€532.0k

Total compensation

CEO salary percentage	100.0%
CEO tenure	9.2yrs
CEO ownership	2.8%
Management average tenure	2.8yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Berndt Axel Modig's remuneration changed compared to Pharvaris's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-€132m
Jun 30 2024	n/a	n/a	-€114m
Mar 31 2024	n/a	n/a	-€106m
Dec 31 2023	€532k	€532k	-€101m
Sep 30 2023	n/a	n/a	-€107m
Jun 30 2023	n/a	n/a	-€92m
Mar 31 2023	n/a	n/a	-€83m
Dec 31 2022	€500k	€500k	-€76m
Sep 30 2022	n/a	n/a	-€49m
Jun 30 2022	n/a	n/a	-€50m
Mar 31 2022	n/a	n/a	-€53m
Dec 31 2021	€414k	€414k	-€43m
Sep 30 2021	n/a	n/a	-€41m
Jun 30 2021	n/a	n/a	-€38m
Mar 31 2021	n/a	n/a	-€29m
Dec 31 2020	€404k	€404k	-€26m

Compensation vs Market: Berndt Axel's total compensation ($USD557.36K) is below average for companies of similar size in the US market ($USD5.54M).

Compensation vs Earnings: Berndt Axel's compensation has increased whilst the company is unprofitable.

CEO

Berndt Axel Modig (65 yo)

9.2yrs

Tenure

€532,000

Compensation

Mr. Berndt Axel Edvard Modig, MBA, CPA, serves as Chief Executive Officer since 2015 and Executive Director of Pharvaris B.V. Mr. Modig served as a Member of the Supervisory Board at Centogene N.V. since A...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Berndt Axel Modig	Co-Founder	9.2yrs	€532.00k	2.77% $ 35.6m
Anna Nijdam	Head of Strategic Finance & Principal Accounting Officer	no data	no data	0.093% $ 1.2m
Stefan Abele	Chief Technology Operations Officer	less than a year	no data	no data
Annick Deschoolmeester	Chief Human Resources Officer	2.2yrs	no data	0.033% $ 422.7k
Peng Lu	Chief Medical Officer	4.8yrs	no data	0.84% $ 10.8m
Anne Lesage	Chief Early Development Officer	no data	no data	0.92% $ 11.9m
Wim Souverijns	Chief Commercial Officer	3.3yrs	no data	0.20% $ 2.6m
David Nassif	CFO & Corporate Secretary	less than a year	no data	no data
Maryann Cimino	Director of Corporate Relations	no data	no data	no data

2.8yrs

Average Tenure

53.5yo

Average Age

Experienced Management: PHVS's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Berndt Axel Modig	Co-Founder	no data	€532.00k	2.77% $ 35.6m
Robert Glassman	Independent Non-Executive Director	3.8yrs	€50.50k	0.061% $ 790.1k
David Meeker	Independent Non-Executive Chair	3.8yrs	€94.00k	0.22% $ 2.9m
Hans J. G. C. Schikan	Independent Vice Chairman	5.3yrs	€61.00k	0.93% $ 12.0m
Elisabeth Bjork	Non-Executive Director	2.9yrs	€45.00k	0.041% $ 523.4k
Viviane Monges	Non-Executive Director	3.3yrs	€62.50k	0.058% $ 751.5k

3.8yrs

Average Tenure

64yo

Average Age

Experienced Board: PHVS's board of directors are considered experienced (3.8 years average tenure).

Pharvaris Management

Management criteria checks 3/4

Key information

Recent management updates

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Announces Resignation of Morgan Conn as Chief Business Officer, Effective October 4, 2024

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Pharvaris N.V. Appoints David Nassif as Permanent Chief Legal Officer

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Recent updates

New major risk - Revenue and earnings growth

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Pharvaris N.V. Announces Resignation of Morgan Conn as Chief Business Officer, Effective October 4, 2024

Co-Founder notifies of intention to sell stock

Pharvaris Expands Development Program for Deucrictibant

Co-Founder notifies of intention to sell stock

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris N.V. Appoints David Nassif as Permanent Chief Legal Officer

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Share price stability

Chief Early Development Officer notifies of intention to sell stock

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Independent Vice Chairman notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Pharvaris: Digging Deep For Sufficient Market Size

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023

New major risk - Shareholder dilution

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Co-Founder notifies of intention to sell stock

Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer

New major risk - Revenue and earnings growth

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

New major risk - Share price stability

Co-Founder notifies of intention to sell stock

Pharvaris N.V. Announces Board Changes

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

Pharvaris Announces Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Pharvaris N.V., Annual General Meeting, Jun 23, 2023

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

Less than half of directors are independent

Pharvaris Presents Data Supporting HAE Drug Development Strategy At the 2022 HAEi Global Leadership Workshop

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris GAAP EPS of -€0.38

Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V., Annual General Meeting, Jun 29, 2022

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris N.V. Appoints Joan Schmidt as Chief Legal Officer

Less than half of directors are independent

High number of new and inexperienced directors

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris reports Q1 results

Independent Non-Executive Director has left the company

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE

Pharvaris B.V. has completed an IPO in the amount of $165.41 million.

CEO Compensation Analysis

CEO

Tenure

Compensation